Prabhudas Lilladher's research report on Divi's Laboratories
Our FY25E/FY26E EPS estimates stands unchanged. Divi’s Laboratories (DIVI) Q1FY25 EBITDA was 5% above our estimate led by higher custom synthesis (CCS) revenues (up 46% YoY). We expect GMs to improve led by better product mix and stable raw material prices. Mgmt. suggested that moderation of raw material prices, increasing RFP and commencement of some CDMO and contrast media contracts, will continue to aid revenues and margins. We expect 26% EBITDA CAGR and 27% PAT CAGR over FY24-26E.
Outlook
At CMP, stock is trading at 50x FY26E EPS. We Maintain our ‘Accumulate’ rating with revised TP of Rs5,000/share, valuing at 50x FY26E EPS.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
